Indian pharmaceutical major Lupin is looking to increase its global footprint and the joint venture announced with Yoshindo of Japan on Wednesday is one more step in that direction.
Lupin is a big player in the cardiovascular, diabetology, asthma, and paediatric space, among others, with global leadership in anti-TB and cephalosporin segment.
It launched 17 products in the U.S. during 2013-14 and 186 cumulative abbreviated new drug application (ANDA) filings with the U.S. FDA in the quarter ended December 2013. It is the fifth largest generics player in the U.S. (5.3 per cent market share by prescription, IMS Health Data) and among top Indian pharma companies by revenues. It ranks among top 10 generic players in Japan and South Africa.
Analysts believe recent developments point to a further push into Europe and attempts to penetrate emerging markets like Brazil, Mexico and China.
It acquired opthalmics company Laboratories Grin in Mexico in March. Vinita Gupta, CEO, Lupin had said the acquisition was ``a reflection of Lupin’s commitment to expand into the Latin American market and build its global speciality business.’’
The Mexican market is believed to be among the fastest growing pharmaceutical markets in the world, valued at over $ 13.5 billion and growing at 9-10 per cent annually.
It acquired Dutch complex injectables firm Nanomi B.V, making a foray into the technology intensive complex injectables space and is also eyeing lucrative segments like inhalation, valued at US$ 23 billion (IMS sales data) annually. It is setting up dedicated facilities for Inhalation research and for complex injectibles in the USA.
Lupin has been aggressive on the human resource front having appointed Theresa Stevens, who was earlier with Aptalis Pharma and Novartis, as Chief Corporate Development Officer for its global operations last week.
It appointed Dr. Maurice Chagnaud as President – Europe & Head of Inhalation strategy.
